KLF9在上皮性卵巢癌组织中的表达及其临床意义

Expression and clinical significance of KLF9 in patients with epithelial ovarian carcinoma

摘要:

目的探讨Kr俟ppel样转录因子9（KLF9）在上皮性卵巢癌中的表达及其临床意义。方法选取63例有完整临床病理资料及随访>5年的石蜡包埋上皮性卵巢癌组织和正常卵巢上皮组织。采用实时荧光定量聚合酶链反应检测KLF9 mRNA在两组卵巢组织中的表达，应用免疫组织化学法分析KLF9 在两组卵巢中的表达，分析KLF9 表达水平与临床病理参数及患者预后的关系。结果63例卵巢癌组织中，KLF9 mRN为正常上皮组织的（0.44±0.693）倍（p <0.05）。上皮性卵巢癌组织中，KLF9高表达15 例（23.8%），低表达48 例（76.2%）；在正常卵巢组织中，KLF9 高表达18 例（60%），低表达12 例（40%），差异有统计学意义（p <0.05）。癌组织中KLF9低表达与上皮性卵巢癌患者的临床分期、淋巴结转、腹腔积液相关（p <0.05）。KLF9 mRNA高表达组中位生存时间46.8个月（95%CI：26，83），高于低表达组的32.6个月[（95%CI：12，74），p =0.002]。肿瘤组织中KLF9阳性细胞高表达组的中位生存时间为50.2 个月（95%CI：32，84），高于KLF9低表达组的31.1 个月[（95%CI：12，79），p =0.001]。多因素COX 生存分析表明，KLF9 mRNA 和KLF9 阳性细胞低表达是影响上皮性卵巢癌预后不良的独立指标[HR=2.64（95%CI：1.14，3.56），p =0.017]和[HR=3.01（95%CI：2.19，4.51）， p=0.010]。结论KLF9 在上皮性卵巢癌组织中表达下调，与上皮性卵巢癌患者预后不良相关。

Abstract:

Objective To investigate the expression of Kr俟ppel-like transcription factor 9 (KLF9) in epithelial ovarian carcinoma and its clinical significance. Methods Sixty -three formalin -fixed paraffin -embedded samples from epithelial ovarian carcinoma patients with 5 -year follow -up and detailed clinicopathological information were selected. The expressions of KLF9 mRNA and protein were detected by qRT -PCR and immunohistochemistry respectively. The relationships of KLF9 with the clinicopathological factors and the prognosis were analyzed. Results The expression of KLF9 mRNA in the epithelial ovarian carcinoma tissues significantly decreased as compared with that in the normal ovarian tissues (p < 0.05).Compared with the normal tissues, the tumor tissues showed a higher rate of KLF9 low-expression (p < 0.05).The low-expression of KLF9 was associated with TNM stage, lymph node metastases and ascetic fluid (p <0.05). The overall survival of the KLF9 mRNA high-expression group was 46.8 months (95% CI: 26, 83),which was significantly longer than 32.6 months (95%CI: 12, 74) of the KLF9 mRNA low-expression group(p < 0.05). In the cancer tissues, the overall survival of the KLF9-positive cell high-expression group was 50.2 months (95% CI: 32, 84), which was significantly longer than 31.1 months (95% CI: 12, 79) of the KLF9-positive cell low-expression group (p < 0.05). Cox regression analysis showed that KLF9 mRNA and KLF9-positive cell low-expression were the poor prognostic markers for epithelial ovarian carcinoma [HR =2.64 (95%CI: 1.14, 3.56),p = 0.017; HR = 3.01 (95% CI: 2.19, 4.51),p = 0.010]. Conclusions The expression of KLF9 is down-regulated in epithelial ovarian carcinoma which is associated with poor prognosis, therefore,KLF9 may serve as a tumor suppressor in the development of epithelial ovarian carcinoma.